Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lintuzumab-based postremission therapy in APL
NCT00016159Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Nov 2000
- Primary completion
- Mar 2007
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lintuzumab in acute promyelocytic leukemia (APL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Reverse Transcriptase-Polymerase Chain Reaction Negativity. Started Nov 2000; status: completed.
02
Drugs
lintuzumab
03
Conditions
acute promyelocytic leukemia (APL)
Beyond the preview
Go deeper on NCT00016159.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00016159.